Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (2025)
9 slides from Bayer's technical presentation, 2025
Slide 1: Effects Of Finerenone On Individual Components Of The Kansas City Cardiomyopathy Questionnaire
Effects Of Finerenone On Individual Components Of The Kansas City Cardiomyopathy Questionnaire In Heart Failure With Mildly Reduced Or Preserved Ejection Fraction Yasuhiro Hamatani, Alexander Peikert, Brian L. Claggett, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Sh
Slide 2: Backgrounds
BACKGROUNDS Patients with heart failure (HF) experience an impaired health status, such as a high symptom burden and activity limitations. Lewis EF, et al. Eur J Heart Fail. 2007;9:83-91. Chandra A, et al. JACC Heart Fail. 2019;7:862-74. In the FINEARTS-HF trial, finerenone improved health statu
Slide 3: Aims
AIMS The FINEARTS-HF trial was a multicenter, double-blind, This prespecified analysis sought randomized clinical trial to investigate the association of comparing finerenone with finerenone with changes in the placebo in adults ≥40 years with HFmrEF or HFpEF. individual 23-item KCCQ components in t
Slide 4: Study Population
STUDY POPULATION Of the 6,001 patients, the KCCQ-OSS (overall summary score) was available for 5,987 at baseline, of whom 5,006 completed the assessment at 12 months. Study flowchart KCCQ-OSS at baseline The total participants (n=6,001) Mean±SD: 63 ± 22 Median (IQR): 65 (46-81) KCCQ-OSS at baseline
Slide 5: Baseline Characteristics
BASELINE CHARACTERISTICS Low tertile Middle tertile High tertile P for (0≤ KCCQ-OSS ≤53) (53< KCCQ-OSS ≤76) (76< KCCQ-OSS ≤100) trend n=2,013 n=1,992 n=1,982 Age (years) 73 ± 10 72 ± 10 71 ± 10 <0.001 Female 58% 44% 34% <0.001 BMI (kg/m2) 31.6 ± 6.5 30.0 ± 5.8 28.3 ± 5.6 <0.001 NYHA III/IV 53% 28% 1
Slide 6: Finerenone Effect On Broad Spectrum Of KCCQ
FINERENONE EFFECT ON BROAD SPECTRUM OF KCCQ Difference in change Swelling in feet/ankles/legs (n=5003) 2.5 (0.9, 4.1) Intimate relationships with loved ones (n=1658) 2.2 (-0.6, 5.1) Bothered by fatigue (n=5002) 2.2 (0.9, 3.5) Individual 23 KCCQ components Ability limitation by fatigue (n=5001) 2.1 (
Slide 7: Finerenone A 5-Years Advantage In Health Status
FINERENONE A 5-YEARS ADVANTAGE IN HEALTH STATUS ✓ Predicted mean KCCQ- OSS at 12 months was Age difference: 5 y plotted against age for (95% CI: 0-9 y) both treatment arms. Finerenone ✓ KCCQ-OSS was inversely related to age, with finerenone shifting Placebo this relationship toward approximately 5 y
Slide 8: Summary Of The Results
SUMMARY OF THE RESULTS ✓ Nominal improvements with finerenone compared to placebo at 12 months were observed across the range of nearly all 23 KCCQ components. ✓ The greatest significant improvements with finerenone were observed in the items related to swelling and fatigue. ✓ The average magnitude
Slide 9: Thank You
THANK YOU 23 Scientific ‘=? Sessions #AHA25